Breann Estes
Family · Cambridge Springs, PANPI 1982244059
Payments from drug & device makers
Across 106 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$434
- Lilly USA, LLC$180
- GSK$174
- Amgen$147
- Pfizer$132
- Abbott$130
- plus $636 from 13 others
What the payments were for
- Food & beverage$1,832100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $434 |
| Lilly USA, LLC | 9 | $180 |
| GSK | 11 | $174 |
| Amgen | 9 | $147 |
| Pfizer | 8 | $132 |
| Abbott | 7 | $130 |
| Exact Sciences | 5 | $99 |
| AstraZeneca | 6 | $97 |
| Boehringer Ingelheim | 6 | $87 |
| AbbVie | 4 | $75 |
| Inspire Medical Systems, Inc. | 3 | $75 |
| Verona Pharma, Inc. | 3 | $60 |
| Merck | 2 | $32 |
| Dexcom, Inc. | 2 | $29 |
| Boston Scientific | 1 | $25 |
| Johnson & Johnson | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$1,832 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 81 | $77,322 |
| OzempicSemaglutide | 55 | $71,047 |
| XareltoRivaroxaban | 74 | $67,535 |
| JardianceEmpagliflozin | 59 | $54,091 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $31,195 |
| MyrbetriqMirabegron | 46 | $24,732 |
| RybelsusSemaglutide | 18 | $22,936 |
| MounjaroTirzepatide | 16 | $19,777 |
| SynjardyEmpagliflozin/Metformin Hcl | 22 | $13,014 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,550 |
| Dexlansoprazole DrDexlansoprazole | 12 | $4,697 |
| Atorvastatin Calcium | 446 | $4,098 |
| Duloxetine Hcl | 132 | $3,828 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 39 | $3,709 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $434 | $93,98473 claims |
| PfizerEliquis | $132 | $77,32281 claims |
| Johnson & JohnsonXarelto | $16 | $67,53574 claims |
| Boehringer IngelheimJardiance, Synjardy | $87 | $67,10581 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $174 | $37,74563 claims |
| Lilly USA, LLCMounjaro | $180 | $19,77716 claims |
| AstraZenecaSymbicort | $97 | $3,48314 claims |
| AbbVieSynthroid | $75 | $1,73950 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,717 family providers in Pennsylvania.
Other family in Cambridge Springs
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.